F3-8-60 / Qualigen Therap - LARVOL DELTA

Poster Highlighting Qualigen Therapeutics’ Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer (GlobeNewswire) - "Qualigen Therapeutics, Inc...today announces a poster presentation on the Company’s Pan-RAS platform at the American Association for Cancer Research (AACR) Special Conference in Breast Cancer Research, held October 19th to 22nd at the Westin San Diego Bayview....Poster highlights included: Our RAS inhibitors suppressed the interaction of RAS with its downstream mitogenic effectors and suppressed RAS signaling pathways (MAPK and RAL pathways) in Luminal B breast cell model systems; Our Pan-RAS compounds inhibited 3D growth at doses that have little effect on normal 2D growth and are active against in vivo xenograft breast tumors and can be orally available."

Preclinical • Breast Cancer • Oncology • Solid Tumor

Poster Highlighting Qualigen Therapeutics’ Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting (GlobeNewswire) - "Qualigen Therapeutics...announces today that a poster featuring the Company’s pan-RAS inhibitor program in pancreatic cancer will be presented as part of the Scientific Program at the American Society of Clinical Oncology’s (ASCO) 2023 Annual Meeting held June 2-6, 2023 in Chicago....In vivo activity was confirmed in xenograft experiments with cell lines and PDX models, and the molecules were shown to co-operate with AMG-510 (sotorasib) (G12C specific inhibitor) and MRTX1133 (G12D specific inhibitor) against pancreatic cancer cell lines."

Preclinical • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor

A novel pan-RAS inhibitor for luminal B breast cancer. (ASCO 2023) - " The current lead, designated RAS-F binds all three main isoforms of RAS at low uM kd and modulates the RAS effector domain in NMR studies... We have developed a pre-clinical pan-RAS inhibitor that is active in vitro and in vivo against Luminal B breast cancer models. The agent also has potential uses against other tumor types partially driven by deregulated wild type RAS such as triple negative breast cancer."

Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • DAB2IP

Qualigen Therapeutics’ Pan-RAS Inhibitor Program Highlighted in Two Abstracts at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting (GlobeNewswire) - "Qualigen Therapeutics, Inc...announces that two abstracts featuring the Company’s pan-RAS inhibitor program will be included in the American Society of Clinical Oncology’s (ASCO) 2023 Annual Meeting Abstract Book. The first abstract shown below was also accepted as a poster to be presented during the ASCO annual meeting to be held June 2-6, 2023 in Chicago."

Preclinical • Breast Cancer • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor

A novel pan-RAS inhibitor for malignant peripheral nerve sheath tumors. (ASCO 2022) - " The current lead, designated RAS-F binds all three main isoforms of RAS at low uM kd and modulates the RAS effector domain in NMR studies... We have developed a pre-clinical pan-RAS inhibitor that is active in vitro and in vivo against MPNST cancer models. The agent also has potential uses against non-tumor manifestations of Neurofibromatosis such as Plexiform and Cutaneous neurofibromas. Funding: NIH 5U01HL127518-03, Kentucky Lung Cancer Research Program CDMRP NF180094 (GJC)."

Brain Cancer • CNS Disorders • Fibrosis • Genetic Disorders • Lung Cancer • Neurofibromatosis • Neurofibrosarcoma • Oncology • NF1

A novel RAS inhibitor for pancreatic ductal adenocarcinoma. (ASCO 2022) - " The current lead, designated RAS-F binds all three main isoforms of RAS at low uM kd and modulates the RAS effector domain in NMR studies... We have developed a pre-clinical pan-RAS inhibitor that is active in vitro and in vivo against pancreatic cancer models. Funding: NIH 5U01HL127518-03, Kentucky Lung Cancer Research Program (GJC), Qualigen Therapeutics LLC."

Hepatology • Lung Cancer • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma

Qualigen Therapeutics (BIO 2022) - "Our therapeutics pipeline includes cancer drug compounds such as QN-302, QN-247 (formerly referred to as AS1411-GNP or ALAN), and RAS-F, as well as STARS, a DNA/RNA-based treatment device. By combining our demonstrated ability to develop and commercialize innovative medical products with the advanced capabilities of leading cancer research centers, we are committed to providing exciting new therapeutic technologies to physicians and patients."

Oncology • Pediatrics

Qualigen Therapeutics’ Pan-RAS Inhibitor Featured in Two Abstracts at American Society for Clinical Oncology (ASCO) 2022 Annual Meeting (GlobeNewswire) - "Qualigen Therapeutics...announces that two abstracts featuring the Company’s RAS inhibitor program will be featured in the American Society for Clinical Oncology’s (ASCO) Annual Meeting Abstract Book, which was released online today....It suppresses xenograft development of human and mouse RAS driven pancreatic tumor cell lines and reduces the growth of a pancreatic cancer PDX. RAS-F is a pre-clinical pan-RAS inhibitor that is active in vitro and in vivo against pancreatic cancer models....RAS-F was shown to bind all three main isoforms of RAS at low uM kd and modulates the RAS effector domain in NMR studies."

Preclinical • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor